Sanofi MOVES-PD: Multicenter, Randomized, Double-blind, Placebo Controlled Study to Assess the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of GZ/SAR402671 in Patients With Early-stage Parkinson’s Disease Carrying a GBA Mutation or Other Pre-specified Variant
Sanofi US Services, Inc. is conducting a clinical trial in Parkinson’s Disease (PD) patients carrying a glucocerebrosidase (GBA) gene mutation (GBA-PD).
You may be eligible to participate in this study if you meet several criteria including the following:
- Diagnosis of PD and are a known heterozygous carrier of a GBA mutation associated with PD
- Age 18 to 80 years
- Have symptoms of PD for at least 2 years
- If you do not already know your GBA status, you can speak with the site personnel to find out how to get tested for the GBA gene.
Status: Recruiting
Learn more at clinicaltrials.gov. If you are interested, please call (650) 770-0205 or email trials@thepi.org.